Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  ACS Chemical Biology

• Publication date

  2013-09-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/cb400592nPMID 24047414PMCID PMC3870039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance

  2013cited by this paper
• Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

  2012cited by this paper
• Mode of Action of Fluoroquinolones

  2012cited by this paper
• Fluoroquinolone and Quinazolinedione Activities against Wild-Type and Gyrase Mutant Strains of Mycobacterium smegmatis

  2011cited by this paper
• Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance

  2010cited by this paper
• Comparison of In Vitro Activities of Fluoroquinolone-Like 2,4- and 1,3-Diones

  2010cited by this paper
• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  2010cited by this paper
• Characterization of the Enzymes Encoded by the Anthrose Biosynthetic Operon of Bacillus anthracis

  2010cited by this paper
• The complexes of metal ions with fluoroquinolones

  2009cited by this paper
• Probing the Differential Interactions of Quinazolinedione PD 0305970 and Quinolones with Gyrase and Topoisomerase IV

  2009cited by this paper
• Quinolones: Action and Resistance Updated

  2009cited by this paper
• Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates

  2008cited by this paper
• Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones

  2008cited by this paper
• DNA topology and topoisomerases

  2008cited by this paper
• Quinolone-Mediated Bacterial Death

  2007cited by this paper
• In Vitro and In Vivo Activities of PD 0305970 and PD 0326448, New Bacterial Gyrase/Topoisomerase Inhibitors with Potent Antibacterial Activities versus Multidrug-Resistant Gram-Positive and Fastidious Organism Groups

  2007cited by this paper
• Etoposide, topoisomerase II and cancer.

  2005cited by this paper
• Fluoroquinolone prescribing in the United States: 1995 to 2002.

  2005cited by this paper
• The quinolones: past, present, and future.

  2005cited by this paper
• Encyclopedia of biological chemistry

  2004cited by this paper
• Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.

  2004cited by this paper
• Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations

  2004cited by this paper
• Quinolone-resistant mutations of the gyrA gene of Escherichia coli

  2004cited by this paper
• DNA Topoisomerases: Type II

  2004cited by this paper
• In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin

  2003cited by this paper
• The interactions of metal ions with quinolone antibacterial agents

  2002cited by this paper
• DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.

  2001cited by this paper
• Pharmacokinetics and Pharmacodynamics of Fluoroquinolones

  2001cited by this paper
• Mechanisms of action of antimicrobials: focus on fluoroquinolones.

  2001cited by this paper
• DNA topoisomerases: structure, function, and mechanism.

  2001cited by this paper
• Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.

  2001cited by this paper
• Pharmcokinetics and Pharmacodynamics of the Fluoroquinolones

  2000cited by this paper
• Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.

  2000cited by this paper
• Etoposide: four decades of development of a topoisomerase II inhibitor.

  1998cited by this paper
• Alteration in the GyrA Subunit of DNA Gyrase and the ParC Subunit of DNA Topoisomerase IV in Quinolone-Resistant Clinical Isolates ofStaphylococcus epidermidis

  1998cited by this paper
• Clinical applications of anticancer drugs targeted to topoisomerase II.

  1998cited by this paper
• Clinical applications of quinolones.

  1998cited by this paper
• Merbarone Inhibits the Catalytic Activity of Human Topoisomerase IIα by Blocking DNA Cleavage*

  1998cited by this paper
• DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.

  1998cited by this paper
• DNA gyrase, topoisomerase IV, and the 4-quinolones

  1997cited by this paper
• Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.

  1997cited by this paper
• Interaction of divalent cations, quinolones and bacteria.

  1994cited by this paper
• Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential

  1993cited by this paper
• Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group

  1992cited by this paper
• Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.

  1992cited by this paper
• Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

  1991cited by this paper
• Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones

  1989cited by this paper
• Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae.

  1989cited by this paper

• From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents

  2025cites this paper
• Machine learning and generative AI in the rational design of DNA gyrase-targeted antibacterials.

  2025cites this paper
• Pharmacological effect of quinazoline-2,4(1H,3H)-dione derivatives: a review.

  2025cites this paper
• Target-Mediated Fluoroquinolone Resistance in Neisseria gonorrhoeae: Actions of Ciprofloxacin against Gyrase and Topoisomerase IV

  2024cites this paper
• Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance

  2024cites this paper
• Synthesis and Antibacterial Evaluation of Ciprofloxacin Congeners with Spirocyclic Amine Periphery

  2023cites this paper
• Topoisomerase II inhibitors design: Early studies and new perspectives.

  2023cites this paper
• Moxifloxacin Metal Complexes: Synthesis, Characterisation, Antimicrobial and Antidiabetic Activities with Docking Studies

  2023cites this paper
• Identification of environmentally biodegradable scaffolds for the benign design of quinolones and related substances

  2023cites this paper
• Development and radiosterilization of new hydrazono‐quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study

  2022cites this paper
• New 1,2,4‐oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity

  2022cites this paper
• Pd(ii)-Catalyzed [4 + 1 + 1] cycloaddition of simple o-aminobenzoic acids, CO and amines: direct and versatile synthesis of diverse N-substituted quinazoline-2,4(1H,3H)-diones

  2021cites this paper
• Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.

  2021cites this paper
• Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.

  2020cites this paper
• A Review of Immunomodulatory Effects of Fluoroquinolones

  2020cites this paper
• Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.

  2020cites this paper
• Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase.

  2020cites this paper
• Recent advances in DNA gyrase-targeted antimicrobial agents.

  2020cites this paper
• Chitosan/poly(dimethylaminoethylmethacrylate-co-hydroxyethylacrylate) based semi-IPN hydrogels and silver nanocomposites: Synthesis, evaluation of amoxicillin release studies, and antibacterial studies

  2019cites this paper
• Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.

  2019influential citation
• A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties.

  2019cites this paper
• Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase IIα and IIβ

  2019cites this paper
• Fluoroquinolone Resistance

  2019cites this paper
• Quinolone antibiotics

  2019cites this paper
• Fluoroquinolone-3-carboxamide amino acid conjugates: Synthesis, antibacterial properties and molecular modeling studies.

  2019cites this paper
• Design, Synthesis and Biological Evaluation of Ciprofloxacin- Peptide Conjugates as Anticancer Agents

  2019cites this paper
• Non-quinolone Topoisomerase Inhibitors

  2018cites this paper
• Bacterial Type II Topoisomerases and Target-Mediated Drug Resistance

  2018cites this paper
• Investigação de resistência adquirida e epidemiologia molecular em enterobactérias produtoras de AmpC cromossômica isoladas de pacientes hospitalizados

  2018cites this paper
• Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site

  2018cites this paper
• When antibiotics turn toxic

  2018cites this paper
• Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.

  2018cites this paper
• New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.

  2018cites this paper
• Synthesis, antimicrobial activity and molecular modeling study of 3-(5-amino-(2H)-1,2,4-triazol-3-yl]-naphthyridinones as potential DNA-gyrase inhibitors.

  2018cites this paper
• Design, synthesis, and evaluation of N-1 Aryl fluoroquinolones for the development of human topoisomerase inhibitors

  2018cites this paper
• Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic

  2017cites this paper
• Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?

  2017cites this paper
• Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase

  2017cites this paper
• Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities

  2017influential citation
• Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance

  2017cites this paper
• Discovery of a New DNA Gyrase A Inhibitor, 4-[(1-methyl-6-nitroquinolin-1-ium-4-yl)amino]-N-[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]benzamide

  2017cites this paper
• Search for Novel Antibacterial Compounds and Targets.

  2017cites this paper
• Effects of DNA Geometry and Topoisomerase II Poisons on Human and Bacterial Type II Topoisomerases

  2017influential citation
• Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis

  2016cites this paper
• The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity

  2016influential citation
• Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase

  2016cites this paper
• Synthesis, characterization, and evaluation of the antimicrobial potential of copper(II) coordination complexes with quinolone and p-xylenyl-linked quinolone ligands.

  2016cites this paper
• A “Double-Edged” Scaffold: Antitumor Power within the 
Antibacterial Quinolone

  2016cites this paper
• Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes 2 from M . tuberculosis 3

  2016cites this paper
• Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones

  2016cites this paper
• Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin

  2015cites this paper
• Mode Of Inhibition of a novel DNA gyrase inhibitor with activity against Neisseria gonorrhoeae Inhibition of Neisseria gonorrhoeae type II Topoisomerases by the Novel Spiropyrimidinetrione AZD 0914 * #

  2015cites this paper
• Design and synthesis of fluoroquinolones to overcome resistance in bacteria

  2015influential citation
• Insights into the Catalytic Mechanism of Eukaryotic and Bacterial Type II Topoisomerases and the Actions of Topoisomerase II Poisons

  2015influential citation
• Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

  2015cites this paper
• Action mechanism of 6, 6'-dihydroxythiobinupharidine from Nuphar japonicum, which showed anti-MRSA and anti-VRE activities.

  2015cites this paper
• Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria

  2015cites this paper
• Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914*

  2015cites this paper
• Synthesis, antibacterial, and DNA-PK evaluation of some novel 6-fluoro-7-(cyclic amino)-2-(thioxo or oxo)-3-substituted quinazolin-4-ones as structural analogues of quinolone and quinazolin-2,4-dione antibiotics

  2015cites this paper
• Safety issues and drug–drug interactions with commonly used quinolones

  2015cites this paper
• Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae

  2014cites this paper
• Bypassing Fluoroquinolone Resistance with Quinazolinediones: Studies of Drug–Gyrase–DNA Complexes Having Implications for Drug Design

  2014cites this paper
• Bacillus anthracis GrlAV96A Topoisomerase IV, a Quinolone Resistance Mutation That Does Not Affect the Water-Metal Ion Bridge

  2014cites this paper
• Mechanism of Quinolone Action and Resistance

  2014cites this paper
• Role of the Water–Metal Ion Bridge in Mediating Interactions between Quinolones and Escherichia coli Topoisomerase IV

  2014cites this paper
• IV: A Quinolone Resistance Mutation that Does Not Affect the

  2014cites this paper